Molecular Pharmacology (USA), Ltd. Stock

Equities

MLPH

US60852T1097

Biotechnology & Medical Research

Market Closed - OTC Markets 09:31:51 2024-04-24 am EDT 5-day change 1st Jan Change
0.0006 USD 0.00% Intraday chart for Molecular Pharmacology (USA), Ltd. 0.00% +59,900.00%
1 month+500.00%
6 months+500.00%
Sales 2013 - Sales 2014 - Capitalization 1.12M
Net income 2013 - Net income 2014 - EV / Sales 2013 -
Net Debt 2013 2.04M Net Debt 2014 2.2M EV / Sales 2014 -
P/E ratio 2013
-5.85 x
P/E ratio 2014
-9.54 x
Employees 1
Yield 2013 *
-
Yield 2014
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
Current month+500.00%
1 month+500.00%
6 months+500.00%
More quotes
1 week
0.00
Extreme 0.0006
0.00
1 month
0.00
Extreme 0.0006
0.01
Current year
0.00
Extreme 0
0.01
1 year
0.00
Extreme 0
0.01
3 years
0.00
Extreme 0
0.01
5 years
0.00
Extreme 0
0.03
10 years
0.00
Extreme 0
0.03
More quotes
Date Price Change Volume
24-04-24 0.0006 0.00% 2,000

Delayed Quote OTC Markets, April 24, 2024 at 09:31 am EDT

More quotes
Molecular Pharmacology (USA) Limited (Molecular USA) is an Australia-based development Stage company together with its subsidiary, Molecular Pharmacology Pty. Ltd. (MPLA) is in the business of developing and commercializing an analgesic and anti-inflammatory molecule known as Tripeptofen. The Company’s over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs (NSAIDs). The licensed products include all products in all dosage forms, formulations, line extensions and package configurations using production method of metallo-polypeptide analgesic and anti-inflammatory activity as an active ingredient marketed by MPLA or its affiliates under the trade name Tripeptofen. The Company and Molecular Pharmacology Pty. Ltd. have no manufacturing facilities.
More about the company